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The induction of inflammatory cytokines during respiratory viral infections contributes to
both disease pathogenesis and resolution. The present studies investigated the role of the
chemokine CXCL10 and its specific receptor, CXCR3, in the host response to pulmonary
respiratory syncytial virus (RSV) infection. Antibody-mediated neutralization of CXCL10
resulted in a significant increase in disease pathogenesis, including airway hyperrespon-
siveness (AHR), mucus gene expression, and impaired viral clearance. When the
pulmonary cytokine levels were examined, only type I IFN and IL-12p70 were significantly
reduced. These latter observations were reflected in reduced dendritic cell (DC) numbers
and DC maturation in the lungs of RSV-infected mice treated with anti-CXCL10.
Neutralization of the only known receptor for CXCL10, CXCR3, resulted in similar increases
in pathogenic responses. When bonemarrow-derived DCwere incubatedwith CXCL10 and
RSV, an up-regulation of type I IFN was observed. In addition, T lymphocytes were also
examined and a significant decrease in the number of RSVM2 peptide-specific CD8+ T cells
was identified. These findings highlight a previously unappreciated role for the
CXCL10:CXCR3 signaling axis in RSV-infected animals by recruiting virus-specific T cells
into the lung and promoting viral clearance.
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Introduction
Respiratory syncytial virus (RSV) infects nearly all infants by age 2
and is the leading cause of bronchiolitis in children worldwide [1].
It is estimated by the CDC that up to 125 000 pediatric
hospitalizations in the United States each year are due to RSV,
at an annual cost of over US$300 000 000 [2]. Despite the
generation of RSV-specific adaptive immune responses, RSV does
not confer protective immunity and recurrent infections through-
out life are common [3, 4]. While RSV is especially detrimental in
very young infants whose airways are small and easily occluded,
RSV is also widely becoming recognized as an important pathogen
in transplant recipients, patients with chronic obstructive
pulmonary disease (COPD), the elderly, as well as likely other
patients with chronic lung disease, especially asthma. Recent data
suggest that mortality for all ages combined have been
approximately 30 000–100 000 from 1990 to 2000, with an
annual average of over 17 000 in the US [5, 6]. These numbers are
likely grossly underestimated, as RSV infection has not been
examined in adults in a consistent manner. Thus, RSV not only
causes significant exacerbated lung disease in young and old, but
also is associated with significant mortality. Although anti-RSV
antibodies are available and appear to alleviate severe disease,
they perform best when given prior to infection, and few other
options exist for combating the RSV infections in susceptible
patient populations [7].
Clinical studies have suggested that the severity of RSV-
induced disease correlates with the influx of leukocytes, resulting
in damage to the airways [3]. Chemokines (chemotactic
cytokines) have been shown to correlate directly to the intensity
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of the inflammatory response and are induced by viral infection. In
particular, a number of studies have demonstrated that CXCL8
(IL-8), CCL3 (MIP-1a), and CCL5 (RANTES) released during the
RSV infection correlate to the most severe cases of RSV infection in
infants [8–10]. More recently, chemokine production has been
linked directly to recognition of pathogen-associated molecular
patterns (PAMP) that are expressed during the viral infection [11,
12]. In particular, the recognition of dsRNA by either TLR3 or RIG-
I pathways induces the production of type I IFN and chemokines,
especially CCL5 and CXCL10 [12]. Blockade of CCL5-mediated
responses in animal models of RSV appears to attenuate disease
pathogenesis by reducing airway hyperreactivity (AHR) and
mucus overproduction [13]. Little information exists on the
potential role of CXCL10 and its receptor CXCR3 in the
development of pathogenesis during RSV infection. The results
from previous studies, together with the one presented here,
indicate that while both CCL5 and CXCL10 are expressed at
significantly high levels in vitro and in vivo during RSV infection,
CXCL10 appears to have a protective role in the host by reducing
viral load and pathogenesis.
Results
Induction/neutralization of CXCL10 in vivo
Our previous studies have demonstrated the temporal production
of CXCL10 during RSV infection [14]. Our first objective in the
current studies was to determine the kinetics of CXCL10 induction
during RSV infection, and evaluate the efficacy of our neutralizing
antibody. BALB/c mice were treated with anti-CXCL10 or control
antibodies, and infected with 105 PFU RSV. The levels of CXCL10
in the lungs were assessed by ELISA assay of lung homogenates.
RSV infection in BALB/c mice resulted in significant induction of
CXCL10 in the lungs. As previously demonstrated, in control
antibody-treated mice, a dramatic induction of CXCL10 protein
was observed beginning at day 3 post infection, and persisting to
day 8 post infection (Table 1). Treatment of mice with neutralizing
antibodies to CXCL10 significantly decreased CXCL10 levels in
the lungs (Table 1). These data demonstrate that RSV infection
results in the dramatic induction of CXCL10 in the lungs, which is
significantly reduced via treatment with neutralizing antibodies.
RSV-induced pathophysiology
In our model, RSV infection in BALB/c mice results in an increase
in AHR, as well as mucus hypersecretion [15]. To determine
whether CXCL10 plays a role in mediating RSV-induced patho-
physiology, mice were treated with control or anti-CXCL10
neutralizing antibodies, infected with RSV, and AHR and mucus
production were assessed. An increase in airway resistance was
observed in response to methacholine in RSV-infected mice
(Fig. 1A). Increased AHR was accompanied by increased
transcription of the mucus associate genes Muc5ac and Gob5
(Fig. 1B). Anti-CXCL10 antibody treatment significantly increased
AHR relative to control antibody-treated mice (Fig. 1A). Similarly,
CXCL10-neutralized animals exhibited increased periodic acid-
Schiff (PAS) staining (Fig. 1B) and increased mucus-associated
gene expression (Fig. 1C). Taken together, these data demonstrate
that neutralization of CXCL10 enhances RSV-induced pathophy-
siology.
Viral clearance
To determine whether CXCL10 plays a role in the clearance of RSV,
we determined viral load via plaque assay and via quantitative PCR
for RSV G protein transcript. The levels of infectious virus (PFU)
were similar in the lungs of control Ig and anti-CXCL10-treated
mice at day 3 post infection (Fig. 2A). At day 8 post infection, PFU
via plaque assaywere below the level of detection. Similarly, RSVG
protein expression in the lungs was similar in both groups at day 3
post infection (Fig. 2B). At day 8, however, significantly more RSV
G protein expression was present in the lungs of CXCL10-
neutralized mice (Fig. 2B). These results suggest that neutraliza-
tion of CXCL10 leads to impaired clearance of RSV from the lungs.
Pulmonary cytokines
The expression of CXCR3 by T cells has generally been associated
with Type 1 cell-mediated responses, Th1 and cytotoxic T1 (Tc1). If
Th1/Tc1 cells utilize CXCL10 in trafficking to the lungs, blockade
of CXCL10 would likely result in a shift in the Th1/Th2 balance in
favor of Th2. To determine whether CXCL10 neutralization results
in an enhanced Th2 response in the lungs, the levels of IL-4, IL-5,
and IFN-c were assessed in control Ig-treated and CXCL10-
neutralized RSV-infected mice, as described in the Materials and
methods. No alterations in IFN-c or Type 2 cytokines were observed
in CXCL10-neutralized mice, relative to controls (Fig. 3A).
However, a significant decrease in the Type 1-promoting cytokine
IL-12p70 was observed in CXCL10-neutralized mice (Fig. 3A).
Additionally, a decrease in Ifna4 mRNA was observed in CXCL10-
neutralized mice (Fig. 3B). Thus, neutralization of CXCL10
decreased IL-12 protein and Ifna4 mRNA in the lungs, but these
results were not associated with an increased Type 2 response in
the lungs.
Table 1. Induction and neutralization of CXCL10 (pg/mL) in the lungs of
RSV infected mice. *p<0.05 vs. Ctrl
Days post infection Ctrl RSV Anti-CXCL10
0 1.06  0.09 0.98  0.07
3 7.44  1.1 3.92  0.38*
8 3.83  0.59 1.83  0.29*
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CXCR3 expression by pulmonary leukocytes
To determine which immune cells are affected by CXCL10
neutralization, we characterized the expression of CXCR3 on a
variety of leukocyte subsets from the lungs of uninfected and RSV-
infected mice. Consistent with reports in the literature, CXCR3
expression was detectable on all cell types assayed, including
CD8 Tcells, CD4 Tcells, B cells, NK cells, monocyte/macrophages,
as well as both myeloid DC (mDC) and plasmacytoid DC (pDC)
(Fig. 4) [16–19]. The frequency of CXCR3 expression was highest
on NK cells and pDC (Fig. 4). Following RSV infection, however,
only pDCmaintained CXCR3 expression at high frequency (Fig. 4).
These data indicate that a variety of cell types in the lungs express
CXCR3 prior to, and during, RSV infection, but only pDC
maintained CXCR3 expression at high frequency.
Lung DC trafficking/maturation
The decreased Ifna4 and IL-12 in the lungs of CXCL10-neutralized
mice led to a focus on lung DC. Resident lung DC (and
macrophages) are among the first immune cells to encounter
respiratory pathogens. Lung DC take up antigen and traffic to
lung-draining lymph nodes, where they subsequently prime T cell
responses. Pulmonary immunity to viruses and other pathogens
also results in the accumulation of large numbers of DC in the
lungs. To determine whether CXCL10 plays a role in the trafficking
of these “inflammatory” DC to the lungs during pulmonary RSV
infection, mice were treated with control or CXCL10 neutralizing
antibodies and the numbers of mDC and pDC in the lungs were
assessed. In control IgG-treated mice, RSV infection resulted in the
dramatic recruitment of mDC to the lungs (Fig. 5A, approximately
Figure 1. Effect of CXCL10 neutralization on RSV-induced pathophysiology. (A) AHRwas assessed in uninfected, control Ig-treated/RSV-infected (Ctrl
RSV) and anti-CXCL10-treated/RSV-infected (aCXCL10) mice by plethysmography on day 8 post infection. Change in resistance represents the
increase over baseline in response tomethacholine challenge. Bars represent themean of tenmice per group + SEM. *p<0.05 vs. uninfected, #p<0.05
vs. control RSV infected. (B) PAS staining in lungs of control Ig-treated/RSV-infected (Ctrl RSV) and anti-CXCL10-treated/RSV-infected (aCXCL10)mice
at day 8 post RSV infection. Histological sections were stained with PAS. (C) The expression of the mucus-associated genes Muc5ac and Gob5 was
determined by real-time PCR of whole lung RNA (day 8 post infection).
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sixfold over uninfected controls – dashed line). Anti-CXCL10-
treated mice had significantly fewer mDC in the lungs (Fig. 5A). A
smaller, but significant increase in pDC was found in the lungs of
RSV-infected mice, relative to uninfected lungs (Fig. 5A). CXCL10
neutralization had no effect on the accumulation of pDC in the
lungs of RSV-infected mice. While the gate used to define pDC
(CD45+, low FSC, low SSC, CD11cint, B220+) may include some
NK DC (*20% DX5+ in both control and CXCL10-neutralized
mice, Table 2), 50% of the CD11c+B220+ cells co-express Gr-1
(Table 2). These data confirm that these cells are predominantly
pDC, and CXCL10 neutralization did not affect pDC trafficking to
the lungs. This result was unexpected, however, as pDC in the
lungs expressed CXCR3 at higher levels than did mDC (Fig. 4B).
CXCL10 neutralization did not affect the recruitment of NK cells or
monocyte/macrophages (Fig. 5A). These results demonstrate that
CXCL10 promotes recruitment of mDC to the lungs during RSV
infection, but since mDC expressed low levels of CXCR3, relative to
pDC, this effect may be indirect.
Pathogen recognition by DC via TLR and other pattern
recognition receptors results in the up-regulation of MHC class II
and costimulatory molecules, collectively referred to as “matura-
tion”. To determine whether CXCL10 plays a role inmodulating DC
maturation, we determined the expression MHC class II and
costimulatory molecules by DC from the lungs of anti-CXCL10-
treated and control RSV-infected mice. The expression of MHC
class II was up-regulated in control RSV-infected mice, relative to
controls (Fig. 5B and C). There was a trend toward increased CD80
and CD86 expression following RSV infection, but this did not
reach statistical significance (data not shown). The up-regulation
of MHC class II by mDC was significantly impaired in CXCL10-
neutralized mice (Fig. 5B and C). These results suggest that
CXCL10 promotes pulmonary DC activation/maturation during
RSV infection.
Figure 3. Effect of CXCL10 neutralization on the production of cytokines
in the lungs of RSV-infected mice at day 8 post infection. Mice were
treated with anti-CXCL10 or control antibodies and infected with RSV.
In (A), cytokine levels were assessed by ELISA of homogenized lung
samples. In (B), the expression of Ifna4was assessed by quantitative RT-
PCR of lung RNA. Bars represent the mean of five mice per group + SEM.
*p<0.05. Similar results were obtained in two independent experi-
ments.
Figure 2. Role of CXCL10 neutralization on the impaired clearance of
RSV from the lungs. (A) The number of infectious RSV particles (PFU) in
the lungs was assessed by plaque assay at day 3 post infection. PFU
were below the limit of detection at day 8 post infection. (B) As a
complementary measure of viral load, expression of the RSV G protein
transcript was assessed at days 3 and 8 post infection. The relative
increase in RSV G protein expression was compared to lungs of control
Ig-treated/RSV-infected (Ctrl)mice. Bars represent themean of fivemice
per group + SEM. *p<0.05 vs. ctrl. Similar results were obtained in two
independent experiments.
Table 2. Expression of pDC and NK associated markers by low FSC/SSC
CD45+CD11c+B220+ in the lungs of RSV infected mice; day 8 post
infection
Ctrl RSV Anti-CXCL10
Gr-1(%) 52.0  3.7% 46.1  5.2%
DX5 (%) 19.2  2.6% 21.1  2.9%
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Pulmonary T cell numbers
We next wanted to determine whether CXCL10 neutralization
would impact T cell responses during RSV infection. To this end,
RSV-infected mice were treated with control or CXCL10-neutraliz-
ing antibodies and the numbers of lung CD4, CD8, and RSVM82–90
Tetramer-specific CD8 T cells were determined from whole lungs.
CXCL10 neutralization resulted in significantly decreased numbers
of CD4, CD8, and RSV M82–90-specific CD8 T cells in the lungs of
RSV-infected mice (Fig. 6). These data demonstrate that CXCL10
promotes RSV-specific T cell responses in the lungs.
CXCR3 blockade and RSV-induced pathophysiology
CXCR3 is the only known receptor for CXCL10 in mice. To
determine whether blockade of CXCR3 altered pathophysiology in
a manner similar to CXCL10 neutralization, we administered anti-
CXCR3 antibodies during RSV infection. Similar to anti-CXCL10,
neutralization of CXCR3 resulted in increased AHR (Fig. 7A),
again suggesting that this receptor-ligand system has an important
role in activation of the appropriate anti-viral response. Addi-
tionally, CXCR3-neutralized mice had significantly increased
Muc5ac expression and a trend toward increased Gob5
(Fig. 7B), indicating that the overproduction of mucus corre-
sponded with the changes in lung function (AHR). These data
Figure 4. (A) Representative gating of DC populations from the lungs of RSV-infected mice. Total lung leukocytes were isolated by enzymatic digest,
and analyzed without further purification by flow cytometry. Monocytes/macrophages (gates I and III) were defined as CD11b+CD11clo and
CD11bloCD11c+; mDCwere defined by lowautofluorescence, CD45+, CD11bhi, CD11chi MHC-II+ (gate II); pDCwere defined by low forward scatter, low
side scatter, CD45R/B220+, CD11cint (right panel). The expression of MHC II by CD11chiCD11bhi mDC is shown in the histogram in the middle panel.
(B) The frequency of CXCR3 expression by various leukocyte subsets from the lungs of uninfected and day 8 RSV-infected mice. Macrophage/
monocyte (gates I, III) and CD11chiCD11bhimDC (gate II) were gated as shown in (A). Similar resultswere obtained in three independent experiments.
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provide supporting evidence that the protective effects of CXCL10
during pulmonary RSV infection are mediated via CXCR3.
CXCL10 promotes Ifna4 induction and limits viral
replication in CXCR3-expressing DC
Our in vivo data demonstrated that CXCL10 neutralization altered
lung DC numbers in the lungs of RSV-infected mice. Our next
objective was to determine whether CXCL10 plays a direct role in
modulating DC. Bone marrow-derived DC (BMDC) were infected
in vitro with RSV (MOI of 1) and treated with medium alone or
CXCL10. BMDC were CD11b+, consistent with published reports,
and expressed moderate levels of CXCR3 (Fig. 8A). RSV infection
of BMDC induced dramatic increases in Ifna4, and CXCL10
treatment of RSV-infected BMDC augmented IFN-a4 mRNA
expression (Fig. 8B). Interestingly, RSV replication/transcription,
as assessed by RSV G protein expression, was significantly
decreased in CXCL10-treated BMDC, compared to DC treated
with medium alone (Fig. 8B). The addition of CXCL10 did not
directly promote RSV-induced IL-12 production or MHC class II
up-regulation. These data suggest that CXCL10 promotes an “anti-
viral state” in CXCR3-expressing DC, but does not directly
influence DC maturation. Taken together with in vivo data, these
results demonstrate that CXCL10 promotes Ifna4.
Figure 5. (A) Absolute numbers of mDC, pDC, NK cells, and monocyte/
macrophages in the lungs of control Ig-treated/RSV-infected (Ctrl RSV)
and CXCL10-neutralized/RSV-infected (aCXCL10) mice at day 8 post
infection. Frequencies were determined by flow cytometry, and
absolute numbers were determined as described in the Materials and
methods. Gating ofmyeloid cellswas done as shown in Fig. 4.Monocytes/
macrophages represent gates I and III defined in Fig. 4. Bars represent
the mean of nine to ten mice per group + SEM. Dashed lines represent
cell numbers in nave animals. *p<0.05. (B) Representative histograms
depict the expression of MHC class II by mDC from the lungs of nave
mice, control Ig-treated/RSV-infected and CXCL10-neturalized/RSV-
infected mice at day 8 post infection. (C) The median fluorescence
intensity (MedFI) of MHC class II staining is shown. Bars represent the
mean of fivemice + SEM. *p<0.03. Similar resultswere obtained in three
independent experiments.
Figure 6. Lung T cell numbers in anti-CXCL10/RSV-infected and control
Ig-treated/RSV-infected mice. The absolute numbers of CD4, CD8, and
RSV M82–90 tetramer
+ T cells at day 8 post infection were determined by
flow cytometric analysis of enzymatically digested lungs. *p<0.05 vs.
control Ig treated mice. Similar results were obtained in two
independent experiments.
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Discussion
The production of chemokines during the initial phases and
throughout the infectious process in the lung provides a key role in
immunity against and regulating pathogenesis of RSV. In the
present study the role of CXCL10 and CXCR3 induced during RSV
infection has been carefully explored using a murine model of
disease. The neutralization of either CXCL10 or CXCR3 led to a
similar exacerbation of disease pathogenesis with significant
increases in AHR and mucus gene expression. These data
correlated with the reduction in DC accumulation and viral
specific CD8+ Tcell numbers. The increased presence of virus gene
expression after blocking this mediator cascade indicates that the
activation event induced by this chemokine-receptor pair is critical
to the function of the anti-viral responses. Furthermore, these
results demonstrate that CXCL10 plays a role in modulating the
host response to pulmonary RSV infection via promoting leukocyte
recruitment, and has a role in the trafficking and function of DC.
The expression of CXCL10 has been observed in several models of
respiratory virus infection, including Sendai, influenza, SARS-
CoV, and adenovirus [20–23], as well as in neurogenic viral
responses [24–28]. Thus, the responses induced by CXCL10 during
the RSV-induced disease appear to be a general mechanism for
responding to and/or clearing viral infections.
Neutralization of CXCL10 resulted in impaired type I IFN and
DC maturation in the lungs of RSV-infected mice. A number of
studies have shown that type I IFN promotes DC maturation and
costimulatory molecule expression [29–33]. Recent studies from
our laboratory have shown that, in the absence of type I IFN
signaling, RSV-infected DC do notmature [34]. Thus, considerable
evidence links type I IFN to DC maturation. Taken together, these
results suggest that a likely mechanism for the DC maturation
defect observed in CXCL10-neutralized mice (and consequently
impaired T cell response) is a defect in the induction of type I IFN.
We suggest that CXCL10 promotes type I IFN in CXCR3-expressing
cells (likely pDC in vivo), which in turn promotes mDCmaturation
via type I IFN.
Clinical studies have suggested that the severity of RSV-
induced disease correlates with the influx of leukocytes that lead
to the damage in the airways [3]. In particular, studies
demonstrated that a number of other chemokines released within
the airways during RSV infection, including CXCL8 (IL-8), CCL3
(MIP-1a), and CCL5 (RANTES), correlate to the most severe cases
of RSV infection in infants [8–10, 35, 36]. Two of these
chemokines, CCL3 and CCL5, have also been shown to be
associated with inflammatory responses in animal models of RSV
infection. CCL3 has been linked to the severity of primary RSV-
induced inflammation as well as with multiple infections with
RSV. Furthermore, Domachowske et al. [37] demonstrated that
infection of mice with paramyxovirus induces increased CCL3
related to eosinophil and PMN recruitment. Likewise, studies
examining CCL5 indicate a significant impact on the pathophy-
siological responses in primary RSV infection as well as the pattern
of leukocyte recruitment and leukotriene release in the lungs
during RSV-induced allergen exacerbated disease [13, 38].
Previous studies have also found that the overproduction of
mucus and development of airway hyperreactivity is directly
related to the expression and activation of CXCR2 (an IL-8 receptor
homolog) in mice [39]. At the same time the overproduction of
CXCL10, a chemokine clearly associated with viral clearance and
disease resolution, is also highly induced by RSV [14, 40, 41]. The
overexpression of CXCR3 and CXCL10 ligand appears to mediate a
protective response to RSV, and therefore this represents a balance
for the CCL5/CCR1-induced pathophysiology. In contrast, using a
combination of reagents to block CCL5 or CCR1–/– mice, numerous
studies have shown that this highly expressed chemokine/receptor
pathway corresponds to a detrimental pathological consequence
[13, 37, 38, 42, 43]. Thus, it appears that the appropriate
activation and recruitment of CXCR3+ DC and T cell populations
mediate a less pathogenic immune environment, while blocking
the CCR1/CCL5-mediated pathway would provide a potential
therapeutic strategy.
Several pathways may induce the production of CXCL10 in the
airways during viral infection. One well-characterized mechanism
via TLR-mediated activation of CXCL10 has been demonstrated in
several viral systems including RSV [12, 44–46]. Initial studies
Figure 7. Effect of CXCR3 neutralization on RSV-induced pathophysiol-
ogy. (A) AHR was assessed in uninfected, control Ig-treated/RSV-
infected (Ctrl RSV) and anti-CXCL10-treated/RSV-infected (aCXCL10)
mice by plethysmography on day 8 post infection. Change in resistance
represents the increase over baseline in response to methacholine
challenge. Bars represent themean of tenmice per group + SEM. (B) The
expression of the mucus-associated genes Muc5ac and Gob5 was
determined by real-time PCR of whole lung RNA (day 8 post infection).
Bars represent the mean of five mice per group from one of two
independent experiments. *p<0.05 vs. uninfected, #p<0.05 vs. control
Ig-treated/RSV infected.
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using poly-I:C to activate CXCL10 production demonstrated that it
was one of the highest expressed cytokines during the activation of
multiple cell populations including epithelial cells, fibroblasts and
astrocytes [44, 47–51]. More recently, the activation of other
dsRNA-mediated pathways have also been identified in the
overproduction of CXCL10, as well as other IFN-inducible
chemokines, including RIG-I and PKR [52–54]. Additionally,
these pathways promote the activation of type I IFN production
that provides additional increases in CXCL10 production, thus
further augmenting its production within the system and
enhancing the anti-viral environment.
The expression of CXCR3 on distinct immune cell populations
may be key for understanding the mechanism of RSV clearance in
the lung. Studies originally identified CXCR3 expression on Th1
CD4+ T cells but not on Th2 T cell populations, indicating a clear
dichotomy in recruitment and function [55, 56]. Subsequent
studies have identified that CD8+ cytotoxic T cells can also
differentially express chemokine receptors, depending upon their
state of activation [57, 58].While there is still a paucity of data that
fully define the receptor patterns on CD8+ Tcells, CXCR3 appears
to be defining for efficient recruitment of cytotoxic T cells for viral
clearance in several infection models [25, 26, 59–62]. A
mechanistic picture of the importance of CXCR3 in effective
Th1 type anti-viral immunity continues to be developed, but also
includes the appropriate recruitment of DC populations [21,
63–66]. In particular, the migration of pDC into the lymph node
from the site of viral infection was found to depend upon CXCR3
providing activation signals for lymph node DC to properly activate
efficient anti-HSV immunity [21]. The latter studies suggested that
CXCR3-recruited pDC provided type I IFN signals in the lymph
node that allowed the activation of the T cell populations. In the
present studies we have also observed that pDC preferentially
express CXCR3. Furthermore, previous studies have demonstrated
a key role of pDC in the clearance of RSV and the maintenance of
an effective, non-pathogenic response to RSV [67, 68]. Overall, our
studies identify a key chemokine receptor system that initiates and
maintains the proper immune environment for anti-viral
responses.
Figure 8. Effect of CXCL10 on type I IFN production and viral replication/transcription in vitro. BMDC were prepared as described in theMaterials and
methods. (A) BMDC were stained with either anti-CXCR3 (shaded) or isotype control (hollow line) antibodies and analyzed by flow cytometry. One
representative histogram is shown. Similar results were obtained in two independent experiments. (B) Effect of recombinant CXCL10 on RSV-
induced expression of Ifna4mRNAand RSVG transcript. BMDCwere infectedwith RSV (MOI of 1) alone, or in the presence of 100 ng/mL CXCL10, and
the levels of Ifna4mRNAandRSVG protein transcriptwere assessed by real-time PCR 24 h after infection. Bars represent theMean of three replicates
+ SEM. *p<0.05 vs. control. Similar results were obtained in two independent experiments. (C) Effect of CXCL10 on RSV-induced IL-12 p70 and MHC
class II expression. BMDC were cultured as in (B), IL-12p70 was measured in the supernatant at 24 h post infection. The expression of MHC class II
was determined by flow cytometry.
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Mice
Female BALB/c mice were obtained from the Jackson Laboratories
(Bar Harbor, ME). Mice were housed under pathogen-free
conditions in enclosed filter-topped cages. Clean food and water
were given ad libitum. The mice were handled and maintained
using microisolator techniques, with daily veterinarian monitor-
ing. Bedding from the mice was transferred weekly to cages of
uninfected sentinel mice that were subsequently bled at weekly
intervals and found to be negative for antibodies to mouse
hepatitis virus, Sendai virus, and Mycoplasma pulmonis. The
University Committee on Use and Care of Animals (UCUCA) at the
University of Michigan approved all studies involving mice.
RSV and infection
RSVA strain was derived from a clinical isolate at the University of
Michigan and was propagated in Hep2 cells. After adsorption,
medium was added to the flask, and the infection was allowed to
proceed until syncytia were observed. The cells were frozen at
–80C overnight, and the supernatant was harvested, clarified,
and aliquoted. Viral titers were determined by plaque assay. For
infections, mice were anesthetized with a mixture of ketamine
(100 mg/kg) and xylazine (10 mg/kg). An incision was made over
the trachea and mice were infected with *1  105 PFU RSV in a
volume of 40 lL via intratracheal injection. The surgical wound
was closed with surgical staples and mice recovered with minimal
visible trauma.
Generation of CXCL10- and CXCR3-neutralizing
antibodies
Rabbit anti-murine CXCL10 was generated by immunization of
rabbits with recombinant protein. Rabbit anti-CXCR3 was
generated by immunizing rabbits with a 16-mer peptide
(PYDYGENESDFSDSPP) corresponding the N terminus of murine
CXCR3, and has been shown to neutralize CXCR3 in vivo [26, 69].
CXCR3 expressing T cells and DC were detected in anti-CXCR3-
treated mice, demonstrating that these antibodies are neutraliz-
ing, but not depleting. Sera from immunized rabbits were titered
by ELISA and verified for minimal cross-reactivity to a panel of
other chemokines and cytokines. Antibodies were purified from
total serum by protein A-based affinity columns and the
concentration of antibody was determined by spectrophotometry.
Neutralizing antibodies (3.5 mg/mouse) were administered via
intraperitoneal injection 1 day prior to RSV infection and then
every 3 days. The efficacy of anti-CXCL10 antibody neutralization
in the lungs is shown in Table 1.
Airway hyperreactivity
AHR was assessed as previously described [15]. Briefly, mice were
anesthetized with sodium pentobarbital, intubated via cannula-
tion of the trachea, and ventilated with a Harvard pump ventilator
(*0.3 mL tidal volume; 120 breaths/min). AHR was measured
using a Buxco mouse plethysmograph and software for calculation
of the measurements. Mice were administered a single optimized
intravenous dose of methacholine (150 mg/kg), and the peak
airway resistance was recorded.
RNA and protein assays
The upper left lobe of mouse lungs was used for protein analysis
and RNAwas isolated from the lower left lobe. Lung samples were
snap-frozen in liquid nitrogen and stored at –70C until use. For
protein assays, lungs were homogenized in buffered saline
containing CompleteTM protease inhibitors (Roche Applied Science,
Indianapolis, IN). The concentration of protein was determined by
sandwich ELISA using commercially available paired antibodies
(R&D Systems, Minneapolis, MN) RNAwas isolated from lower left
lobes of lungs using TRIzol (Invitrogen, Carlsbad, CA), and*5 lg
total RNA was reverse transcribed in a volume of 25 lL. Real-time
PCRwas performed on cDNA using commercially available primers
for GAPDH, and custom designed primers for RSV G protein
transcript, Gob-5, and Muc5ac, as previously described [39]. Ifna4
expression was determined using SYBR green I dye, using the
followingprimer sequences: Ifna4F:CCTGTGTGATGCAGGAACC,
Ifna4 R: TCA CCT CCC AGG CAC AGA. Gene expression was
normalized to GAPDH before the fold change was calculated.
Histology
Right lobes of the lungs were removed and immediately fixed in
10% neutral buffered formalin. Lung samples were subsequently
processed, embedded in paraffin, sectioned, and placed on
L-lysine-coated slides. PAS staining was done to identify mucus
and mucus-secreting cells.
Lung and lymph node leukocyte isolation
Lung leukocytes were isolated from enzyme-dispersed lung tissue.
Right lungs from eachmouse were excised, washed in PBS, minced
and digested enzymatically for 45 min in 15 mL/lung of digestion
buffer [RPMI, 5% FBS, 1 mg/mL collagenase (Roche Applied
Science), and 30 lg/mL DNase (Sigma-Aldrich, St Louis, MO)].
Lung-associated lymph nodes were dispersed similarly to lungs,
but using only 5 mL digestion buffer. Following erythrocyte lysis
using ammonium chloride (NH4Cl) buffer, cells were washed, and
resuspended in media (RPMI, 5% FBS). Total lung leukocyte
numbers were assessed in the presence of trypan blue using a
hemocytometer; viability was >85%.
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Flow cytometry
Leukocytes were washed and resuspended at a concentration of
107 cells/mL in Flow Buffer (PBS+ 1% FBS + 0.1% NaN3; Sigma),
Fc receptors were blocked by the addition of anti-CD16/32 (Fc
blockTM; BD Biosciences, San Jose, CA). Following Fc receptor
blocking, 106 cells were stained, in a final volume of 120 lL in
12  75 mm polystyrene tubes (BD Biosciences) for 20 min at
4C. Leukocytes were stained with the following mAb, according
to the manufacturer's instructions: CD4 (RM4–5), CD8a
(5H10–1), CD45 (30-F11), CD45R/B220 (RA3–6B2), CD11b
(M1/70), CD11c (HL3), CD19 (1D3), NK (DX5), I-Ad (AMS-
32.1), Gr-1 (RB6–8C5) (BD Biosciences), and CXCR3 (R&D
Systems). Cells were washed twice with Flow buffer, resuspended
in 100 lL and 200 lL 4% formalin was added to fix the cells. A
minimum of 75 000 events was acquired on a dual-laser Cytomics
FC500TM flow cytometer (Beckman Coulter, Fullerton, CA) and
analyzed using FlowjoTM software (Treestar, Ashland, OR).
Classical mDC were defined by the following parameters: low
autofluorescence, CD45+, CD11bhi, CD11chi MHC-II+. pDC were
defined as: low forward scatter, low side scatter, CD45R/B220+,
CD11cint. In some experiments, CD8+Tcells were stainedwith RSV
M82–90 tetramer (NIH Tetramer Core, Emory University, Atlanta,
GA). RSV M82–90 has been previously shown to be the dominant
CD8+ epitope during RSV infection in BALB/c mice [70].
BMDC culture
DC were grown from mouse bone marrow using minor modifica-
tion of an establish method [71]. Bone marrow cells were flushed
from the femurs and tibias of nave BALB/c mice. Bone marrow
cells were seeded at 2  105/mL in 30 mL BMDC media (RPMI+
10% FBS, 1% Pen-Strep, 1% nonessential amino acids, 1% sodium
pyruvate, 1% L-glutamine, 5  10–5 M 2-mercaptoethanol) with
10 ng/mL recombinant GM-CSF (R&D) in T150 flasks. At day 2,
another 15 mL BMDC media + GM-CSF was added to the culture.
At days 4, 6, and 8, half of the media was removed, centrifuged
and the cell pellet added back to the culture with fresh media +
GM-CSF. Nonadherent cells were harvested at day 10, and the
resulting cells were >85% CD11c+. In some experiments, BMDC
were infected with virus at an MOI of 1, and/or stimulated with
recombinant CXCL10 (R&D).
For airway responses and cytokine levels, p values were calculated
using the two-tailed student's t-test, assuming equal or unequal
variance, as dictated by F test. For quantitative real-time PCR,
statistical comparisons were made by the same methods, except
that p values were calculated based on cycle numbers normalized
to GAPDH controls, before conversion to fold increases. p values of
<0.05 were considered statistically significant.
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